For research use only, not for therapeutic use.
ARV-825(Cat No.:I002360)is a novel proteolysis-targeting chimera (PROTAC) that targets and degrades the BET (bromodomain and extra-terminal) family of proteins. By recruiting the E3 ubiquitin ligase to BET proteins, ARV-825 facilitates their ubiquitination and subsequent degradation by the proteasome. This mechanism disrupts the transcription of genes critical for cancer cell growth and survival. ARV-825 shows potential in treating hematologic malignancies and solid tumors, offering a unique therapeutic approach by degrading rather than inhibiting oncogenic proteins. Its efficacy and specificity make ARV-825 a promising candidate in cancer therapy research.
Catalog Number | I002360 |
CAS Number | 1818885-28-7 |
Molecular Formula | C46H47ClN8O9S |
Purity | 98% |
Target | BRD4 |
Solubility | 10 mM in DMSO |
Appearance | Solid powder |
Storage | Store at -20°C |
IC50 | <1nM (DC50) |
IUPAC Name | 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-N-[4-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]phenyl]acetamide |
InChI | InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1 |
InChIKey | RWLOGRLTDKDANT-TYIYNAFKSA-N |
SMILES | CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)NC4=CC=C(C=C4)OCCOCCOCCOCCNC5=CC=CC6=C5C(=O)N(C6=O)C7CCC(=O)NC7=O)C8=CC=C(C=C8)Cl)C |